FDA approves first biosimilar for the treatment of certain breast and stomach cancers

December 1, 2017

Responsive image

SILVER SPRING, Md., Dec. 1, 2017 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal…

Category: Precious Metals